More Related Content
Similar to Nucleotide-Based Diagnostic for Infectious Diseases
Similar to Nucleotide-Based Diagnostic for Infectious Diseases (20)
More from kphodel
More from kphodel (20)
Recently uploaded
Recently uploaded (20)
Nucleotide-Based Diagnostic for Infectious Diseases
- 1. Nucleotide-based Diagnostic for COVID-19 and Other Infectious Diseases January 27, 2021
- 2. What is the problem? 715,000 cases/day While companies were working on a rapid antigen test, COVID-19 infections were running wild https://ourworldindata.org/covid-cases
- 3. What is the problem? https://ourworldindata.org/covid-cases SARS-CoV2 Genome Sequenced Deployment of Rapid Ab Test While companies were working on a rapid antigen test, COVID-19 infections were running wild 7 Month Development Time
- 4. What is the problem? https://ourworldindata.org/covid-cases Nucleotide-Based Diagnostic SARS-CoV2 Genome Sequenced 1 Month Development Time
- 5. How does product/service solve problem? Faster to develop Simpler to use Adaptable to new viruses capture reporter Our Test Is:
- 6. What is the market use? Highly demanded during new infectious diseases Absent from the market Minimal competition Early diagnostic test kits are:
- 7. What is the market use? Highly demanded during new infectious diseases Absent from the market Minimal competition or or Early diagnostic test kits are: Alternative Market Applications: wide-market utility in research labs
- 8. What competition exists? • Antigen tests are the gold standard for viral testing (Abbott Labs, etc.) • However these take months (~7) to develop • RT-PCR testing is the first viable testing done for emerging diseases • Results take days-to- one week to return • In the meantime…
- 9. What is the status of the intellectual property? • Patent pending on Nucleotide-Based Infectious Disease Diagnostic Test • Patents in preparation: – Nucleotide-Based Reporter Adaptors – Amplification Reagent for Immunoassays
- 10. What is the stage of development? -0.4 -0.2 0 0.2 0.4 0.6 0.8 1 1.2 1.4 positive control scrambled target negative control 100nM 10nM 1nM 100pM OD370 LOD for oligonucleotide ELISA Early proof of principle tests have been successful Methods will be developed for sample processing and detection of physiological concentrations of virus
- 11. What is needed for further development? • Business Partner (CEO) • Support for Preclinical Development • Clinical Connection for Final Validation • Equipment and Consumables • Scaling to Production
Editor's Notes
- We were caught flat-footed by COVID-19. Even when we identified the organism causing the disease and sequenced its genome, we were still unable to engage a rapid testing regimen to do effective monitoring and contact tracing. This led to the uncontrolled spread of disease across the globe
- We were caught flat-footed by COVID-19. Even when we identified the organism causing the disease and sequenced its genome, we were still unable to engage a rapid testing regimen to do effective monitoring and contact tracing. This led to the uncontrolled spread of disease across the globe
- We were caught flat-footed by COVID-19. Even when we identified the organism causing the disease and sequenced its genome, we were still unable to engage a rapid testing regimen to do effective monitoring and contact tracing. This led to the uncontrolled spread of disease across the globe
- In addition to faster deployment, our nucleotide-based test would be easier to use, require less training, less equipment, and have faster turn-around time between test and result.
- The COVID-19 diagnostic is just an example of an adaptive test capable of being used for numerous emerging infectious diseases. Furthermore, the development of this diagnostic has led to the invention of several related reagent types which could be used in numerous laboratory applications including Flow Cytometry, Western Blotting, and ELISAs.
- The COVID-19 diagnostic is just an example of an adaptive test capable of being used for numerous emerging infectious diseases. Furthermore, the development of this diagnostic has led to the invention of several related reagent types which could be used in numerous laboratory applications including Flow Cytometry, Western Blotting, and ELISAs.
- There is competition for this diagnostic. However, early-adaptable tests tend to take longer times and greater costs to process samples and provide results. Rapid, simple tests like the antibody test take many months to develop. This results in a window of opportunity for a simple, rapid test that can be developed early in an epidemic.
- A provisional patent has been filed for the diagnostic test, while we are developing data to support additional applications for related products.
- We have currently generated proof of principle data showing that both the concepts for the diagnostic test and the reagent labeling technology work well. Further development is required in developing the amplification reagent required to detect smaller concentrations of material as found in physiological samples. We are